Spero Therapeutics CEO Ankit Mahadevia's 2019 pay jumps 148% to $1.8M

Spero Therapeutics reports 2019 executive compensation

By ExecPay News

Published: September 30, 2020

Spero Therapeutics reported fiscal year 2019 executive compensation information on September 30, 2020.
In 2019, three executives at Spero Therapeutics received on average a compensation package of $1.2M, a 43% increase compared to previous year.
Average pay of disclosed executives at Spero Therapeutics
Ankit Mahadevia, Chief Executive Officer, received $1.8M in total, which increased by 148% compared to 2018. 42% of Mahadevia's compensation, or $753K, was in option awards. Mahadevia also received $250K in non-equity incentive plan, $497K in salary, $285K in stock awards, as well as $792 in other compensation.
Christina Larkin, Chief Operating Officer, received a compensation package of $943K, which increased by 77% compared to previous year. 42% of the compensation package, or $394K, was in salary.
David Melnick, Chief Medical Officer, earned $936K in 2019, a 43% decrease compared to previous year.

Related executives

Ankit Mahadevia

Spero Therapeutics

Chief Executive Officer

Christina Larkin

Spero Therapeutics

Chief Operating Officer

David Melnick

Spero Therapeutics

Chief Medical Officer

You may also like

Source: SEC filing on September 30, 2020.